Zur Kurzanzeige

2016-09-16Zeitschriftenartikel DOI: 10.1111/tid.12582
Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation
dc.contributor.authorVoigt, Sebastian
dc.contributor.authorHofmann, Jörg
dc.contributor.authorEdelmann, Anke
dc.contributor.authorSauerbrei, Andreas
dc.contributor.authorKühl, J. S.
dc.date.accessioned2018-05-07T20:22:08Z
dc.date.available2018-05-07T20:22:08Z
dc.date.created2017-08-11
dc.date.issued2016-09-16none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/rewtL1lEy8cM/PDF/23Wk9YgakkjiM.pdf
dc.identifier.urihttp://edoc.rki.de/176904/2752
dc.description.abstractInfections with adenovirus (AdV) and herpesviruses can result in considerable morbidity and mortality in pediatric hematopoietic stem cell transplant (SCT) recipients. Herpes simplex virus (HSV) reactivations are usually prevented by acyclovir (ACV) prophylaxis, whereas cidofovir (CDV) has been used off indication to manage AdV infections. We report a child with myelodysplastic syndrome undergoing multiple SCT, who experienced HSV-1 disease including severe mucositis and herpetic whitlow, as well as high viral load AdV DNAemia. Both ACV and CDV were ineffective; however, viral loads were decreased with brincidofovir, resulting in viral clearance. A subsequent Epstein–Barr virus disease with relevant meningoencephalitis responded to rituximab.eng
dc.language.isoger
dc.publisherRobert Koch-Institut, Infektionskrankheiten / Erreger
dc.subjectViral/bloodeng
dc.subjectHumanseng
dc.subjectFemaleeng
dc.subjectDNAeng
dc.subjectChild Preschooleng
dc.subjectDrug Resistance Viraleng
dc.subjectViral Loadeng
dc.subjectAntiviral Agents/therapeutic useeng
dc.subjectImmunocompromised Hosteng
dc.subjectAcyclovir/administration & dosageeng
dc.subjectAcyclovir/therapeutic useeng
dc.subjectAdenoviridae/isolation & purificationeng
dc.subjectAdenoviridae/physiologyeng
dc.subjectAdenovirus Infections Human/bloodeng
dc.subjectAdenovirus Infections Human/drug therapyeng
dc.subjectAdenovirus Infections Human/virologyeng
dc.subjectAntibiotic Prophylaxiseng
dc.subjectAntiviral Agents/administration & dosageeng
dc.subjectCytosine/administration & dosageeng
dc.subjectCytosine/analogs & derivativeseng
dc.subjectCytosine/therapeutic useeng
dc.subjectEpstein-Barr Virus Infections/bloodeng
dc.subjectEpstein-Barr Virus Infections/drug therapyeng
dc.subjectEpstein-Barr Virus Infections/virologyeng
dc.subjectFoscarnet/administration & dosageeng
dc.subjectFoscarnet/therapeutic useeng
dc.subjectHematopoietic Stem Cell Transplantation/adverse effectseng
dc.subjectHerpes Simplex/drug therapyeng
dc.subjectHerpes Simplex/virologyeng
dc.subjectHerpes Zoster/drug therapyeng
dc.subjectHerpes Zoster/virologyeng
dc.subjectHerpesvirus 1 Human/isolation & purificationeng
dc.subjectHerpesvirus 3 Human/isolation & purificationeng
dc.subjectHerpesvirus 4 Humaneng
dc.subjectMeningoencephalitis/drug therapyeng
dc.subjectMeningoencephalitis/virologyeng
dc.subjectMucositis/drug therapyeng
dc.subjectMucositis/virologyeng
dc.subjectMyelodysplastic Syndromes/surgeryeng
dc.subjectOrganophosphonates/administration & dosageeng
dc.subjectOrganophosphonates/therapeutic useeng
dc.subjectRituximab/administration & dosageeng
dc.subjectRituximab/therapeutic useeng
dc.subject.ddc610 Medizin
dc.titleBrincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10055719
dc.identifier.doi10.1111/tid.12582
dc.identifier.doihttp://dx.doi.org/10.25646/2677
local.edoc.container-titleTransplant Infectious Disease
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://onlinelibrary.wiley.com/doi/10.1111/tid.12582/full
local.edoc.container-publisher-nameWiley
local.edoc.container-volume18
local.edoc.container-issue5
local.edoc.container-year2016

Zur Kurzanzeige